Article

Rosuvastatin for Primary Prevention in Older Persons With Elevated C-Reactive Protein and Low to Average Low-Density Lipoprotein Cholesterol Levels: Exploratory Analysis of a Randomized Trial

Universität Ulm, Ulm, Baden-Württemberg, Germany
Annals of internal medicine (Impact Factor: 17.81). 04/2010; 152(8):488-96, W174. DOI: 10.1059/0003-4819-152-8-201004200-00005
Source: PubMed

ABSTRACT

Randomized data on statins for primary prevention in older persons are limited, and the relative hazard of cardiovascular disease associated with an elevated cholesterol level weakens with advancing age.
To assess the efficacy and safety of rosuvastatin in persons 70 years or older.
Secondary analysis of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin), a randomized, double-blind, placebo-controlled trial.
1315 sites in 26 countries randomly assigned participants in JUPITER.
Among the 17 802 participants randomly assigned with low-density lipoprotein (LDL) cholesterol levels less than 3.37 mmol/L (<130 mg/dL) and high-sensitivity C-reactive protein levels of 2.0 mg/L or more without cardiovascular disease, 5695 were 70 years or older.
Participants were randomly assigned in a 1:1 ratio to receive 20 mg of rosuvastatin daily or placebo.
The primary end point was the occurrence of a first cardiovascular event (myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from cardiovascular causes).
The 32% of trial participants 70 years or older accrued 49% (n = 194) of the 393 confirmed primary end points. The rates of the primary end point in this age group were 1.22 and 1.99 per 100 person-years of follow-up in the rosuvastatin and placebo groups, respectively (hazard ratio, 0.61 [95% CI, 0.46 to 0.82]; P < 0.001). Corresponding rates of all-cause mortality in this age group were 1.63 and 2.04 (hazard ratio, 0.80 [CI, 0.62 to 1.04]; P = 0.090). Although no significant heterogeneity was found in treatment effects by age, absolute reductions in event rates associated with rosuvastatin were greater in older persons. The relative rate of any serious adverse event among older persons in the rosuvastatin versus placebo group was 1.05 (CI, 0.93 to 1.17).
Effect estimates from this exploratory analysis with age cut-point chosen after trial completion should be viewed in the context of the overall trial results.
In apparently healthy older persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin reduces the incidence of major cardiovascular events.
AstraZeneca.

Download full-text

Full-text

Available from: James Shepherd, Jan 09, 2014
  • Source
    • "Dans une sous-analyse de l'étude JUPITER portant sur 5695 personnes de plus de 70 ans traitées en prévention primaire par rosuvastatine 20 mg, des résultats similaires étaient observés avec une réduction des évènements CV de 39 % (p < 0,001). Il n'y avait pas de réduction significative de la mortalité cardiovasculaire (RR 0,83 [IC95 % : 0,47–1,48] ; p = 0,53), ni de la mortalité toute cause (RR = 0,80 [IC95 % : 0,62–1,04] ; p = 0,09) [9]. Dans l'étude ASCOT-LLA évaluant l'atorvastatine 10 mg chez des patients hypertendus porteurs de trois autres facteurs de risque CV et initialement publiée en 2003 [10], les auteurs ont "
    [Show abstract] [Hide abstract]
    ABSTRACT: Les statines prescrites en prévention primaire avant 75 ans permettent de réduire les évènements cardiovasculaires de 20 à 30 % et la mortalité de 10 % au prix d’effets indésirables acceptables. Nous avons cherché à savoir si ces résultats persistaient après 75 ans.
    Full-text · Article · Nov 2015
  • Source
    • "Chiral drugs contain at least one chiral center, resulting in 2n−1 pairs of enantiomers. Widely used chiral drugs, such as rosuvastatin, duloxetine and salbutamol, play an important role in treating human diseases1,2,3. In the environment of living systems, specific binding between molecules (eg, enzymes, receptors, transporters, and DNA) is required for their medicinal effect. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Chiral drugs show distinct biochemical and pharmacological behaviors in the human body. The binding of chiral drugs to plasma proteins usually exhibits stereoselectivity, which has a far-reaching influence on their pharmacological activities and pharmacokinetic profiles. In this review, the stereoselective binding of chiral drugs to human serum albumin (HSA), α1-acid glycoprotein (AGP) and lipoprotein, three most important proteins in human plasma, are detailed. Furthermore, the application of AGP variants and recombinant fragments of HSA for studying enantiomer binding properties is also discussed. Apart from the stereoselectivity of enantiomer-protein binding, enantiomer-enantiomer interactions that may induce allosteric effects are also described. Additionally, the techniques and methods used to determine drug-protein binding parameters are briefly reviewed.
    Full-text · Article · Jul 2013 · Acta Pharmacologica Sinica
  • Source
    • "A decrease of CRP of 1 mg/ml as seen in this study could be of clinical significance in certain individuals as values of CRP above 3 mg/ml are associated with a two-fold increase in risk of a myocardial infarction in the following three years (Ridker et al., 2000). In addition, in a trial of elderly people with hyperlipidemia in whom a statin decreased the CRP below 5 mg/l, there was almost a 50% reduction of major cardiovascular events (Glynn et al., 2010). Some studies have suggested that the efficacy of mindfulness intervention does not correlate with the length of time spent on the didactic practice and that shorter or less frequent training sessions are effective (Carmody and Baer, 2009). "
    [Show abstract] [Hide abstract]
    ABSTRACT: We have developed a low dose Mindfulness-Based Intervention (MBI-ld) that reduces the time committed to meetings and formal mindfulness practice, while conducting the sessions during the workday. This reduced the barriers commonly mentioned for non-participation in mindfulness programs. In a controlled randomized trial we studied university faculty and staff (n=186) who were found to have an elevated CRP level,>3.0mg/ml, and who either had, or were at risk for cardiovascular disease. This study was designed to evaluate if MBI-ld could produce a greater decrease in CRP, IL-6 and cortisol than an active control group receiving a lifestyle education program when measured at the end of the 2month interventions. We found that MBI-ld significantly enhanced mindfulness by 2-months and it was maintained for up to a year when compared to the education control. No significant changes were noted between interventions in cortisol, IL-6 levels or self-reported measures of perceived stress, depression and sleep quality at 2-months. Although not statistically significant (p=.08), the CRP level at 2-months was one mg/ml lower in the MBI-ld group than in the education control group, a change which may have clinical significance (Ridker et al., 2000; Wassel et al., 2010). A larger MBI-ld effect on CRP (as compared to control) occurred among participants who had a baseline BMI <30 (-2.67mg/ml) than for those with BMI >30 (-0.18mg/ml). We conclude that MBI-ld should be more fully investigated as a low-cost self-directed complementary strategy for decreasing inflammation, and it seems most promising for non-obese subjects.
    Full-text · Article · Oct 2012 · Brain Behavior and Immunity
Show more